Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Sci Rep. 2018 Oct 30;8(1):16007. doi: 10.1038/s41598-018-34495-4.
This study aimed to address the association between the usage of antibiotics to treat nontuberculous mycobacteria (NTM) infection and the risk of Sjögren's syndrome (SS). We identified 5,553 patients with newly diagnosed SS between 2002 and 2013 using Taiwan's National Health Insurance Research Database and compared them with 83,295 non-SS controls matched (1:15) for age, sex, and the year of their first SS diagnosis. An increased risk of SS was found in patients receiving new macrolides (adjusted odds ratios (aOR) 1.95, 95% confidence intervals (CI) 1.80-2.11), fluoroquinolones (aOR 1.52, 95% CI 1.41-1.64), and tetracyclines (aOR 1.69, 95% CI 1.59-1.79) compared with non-SS controls after adjusting for the Charlson comorbidity index, bronchiectasis and Helicobacter pylori infection. Notably, the association was consistent among each antibiotic in these three groups of antibiotics. In contrast to these three groups of antibiotics, the use of amikacin tended to have a negative association with incident SS (aOR 0.68, 95% CI 0.53-0.87). In conclusion, new macrolides, fluoroquinolones and tetracyclines were associated with a higher incidence of SS. These findings indicate the need for vigilance of SS in prescribing these antibiotics and warrant further mechanistic studies.
本研究旨在探讨治疗非结核分枝杆菌(NTM)感染时使用抗生素与干燥综合征(SS)发病风险之间的关联。我们利用台湾全民健康保险研究数据库,在 2002 年至 2013 年间确定了 5553 例新发 SS 患者,并与 83295 例年龄、性别和首次 SS 诊断年份相匹配的非 SS 对照进行比较。与非 SS 对照组相比,接受新大环内酯类(调整后的优势比[aOR]1.95,95%置信区间[CI]1.80-2.11)、氟喹诺酮类(aOR 1.52,95%CI 1.41-1.64)和四环素类(aOR 1.69,95%CI 1.59-1.79)治疗的患者发生 SS 的风险增加,在调整 Charlson 合并症指数、支气管扩张症和幽门螺杆菌感染后。值得注意的是,在这三组抗生素中,每种抗生素的相关性都是一致的。与这三组抗生素不同,阿米卡星的使用与 SS 发病呈负相关(aOR 0.68,95%CI 0.53-0.87)。总之,新大环内酯类、氟喹诺酮类和四环素类与 SS 发病率升高有关。这些发现表明,在开具这些抗生素时需要警惕 SS,并需要进一步开展机制研究。